Our goal is to help you transition from feeling hesitant to feeling empowered in your health journey
Inhibitors of DPP-4, such as sitagliptin, vildagliptin and linagliptin, inhibit DPP-4, resulting in an increase of incretin and GLP-1 secretion (Figure 1), leading to an improvement in plasma glucose control without inducing hypoglycemia or increasing the body weight.69 Both types of drugs are barely metabolized in the liver and are excreted unchanged by the kidney;70 thus, they seem to be safe in cirrhotic patients.71 Unlike the old antidiabetic drugs, their pharmacodynamic characteristics have been assessed in patients with varying degrees of hepatic impairment and their safety has been assessed in studies comprising large number of individuals
Dashti HS, Mogensen KM
The public should understand that these medications are tools for health, not barriers to love or tradition, and that families can find new ways to honor both their heritage and their well-being. In her email, Stanford reminds us that GLP-1 use isnt just about the individual
De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA et al
